SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

MEDICAMEN BIOTECH

BSE: 531146 29 Jun 2025
Healthcare
₹ 404
Medicamen Biotech Ltd. specializes in Pharmaceuticals within the Healthcare sector.

MEDICAMEN BIOTECH - Share Price & Details

Market Cap
₹563.0
High /Low
630.0 / 375.0
Stock P/E
85.8
Book Value
₹167.0
Dividend Yield
0.24
ROCE
5.39
ROE
₹3.13
Face Value
10.0
PEG Ratio
-6.49
EVEBITDA
₹29.4
Debt
33.2
CMP / FCF
-48.1
Debt to equity
₹0.16
NP Ann
6.56
High price all time
1,225
Piotroski score
₹3.0
Graham Number
145.0
No. Eq. Shares
1.36
Net CF
₹-11.0
Net profit
6.56
Price to book value
2.48
Interest Coverage
₹4.13
Low price all time
4.75
Industry PE
32.7
Reserves
₹200
Free Cash Flow
₹-9.26

Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
LOOKS HEALTH SERVICES LIMITEDNANANANA5.11256.0
Triochem Products Ltd.,NANANANA0
MEDICAMEN BIOTECH LTD.NANANANA563.085.8
ZIM Laboratories Limited1104.4348.841087.331.0151842.5
NECTAR LIFESCIENCES LTD.NANANANA49629.2

Peer Comparison Chart


About MEDICAMEN BIOTECH

Medicamen Biotech Ltd., with Security Code 531146, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.


Latest News

Has Medicamen Biotec declared dividend?

(07 Jun 2025)
Yes, Medicamen Biotech Ltd has declared a 10% dividend, amounting to ₹1 per share, with an ex-date of September 19, 2024.
Read more →

Medicamen Biotech Faces Technical Trend Shift Amidst Bearish Market Indicators

(05 Jun 2025)
Medicamen Biotech has experienced a recent decline in stock price, reflecting a challenging performance with a one-year return of -16.61%.
Read more →

Medicamen Biotech rallies after securing USFDA approval for Bortezomib injection

(03 Jun 2025)
Medicamen Biotech soared 5.39% to Rs 440 after the company has received its first Abbreviated New Drug Application (ANDA) approval from the...
Read more →

MEDICAMEN BIOTECH RALLIES AFTER SECURING USFDA APPROVAL FOR BORTEZOMIB INJECTION

(03 Jun 2025)
The ANDA pertains to Bortezomib for Injection, 3.5 mg single-dose vial. The USFDA has determined that the product is bioequivalent and...
Read more →

Medicamen Biotech to hold board meeting

(03 Jun 2025)
Medicamen Biotech will hold a meeting of the Board of Directors of the Company on 30 May 2025.
Read more →

Medicamen Biotech Reports Mixed Financial Results Amidst Operational Challenges in March 2025

(31 May 2025)
Medicamen Biotech's financial results for the quarter ending March 2025 reveal mixed performance in the pharmaceuticals sector.
Read more →